Laboratory Costs in the Context of Disease (Laboratory Management) Laboratory Costs in the Context of Disease (Laboratory Management)

Laboratory Costs in the Context of Disease (Laboratory Management‪)‬

Clinical Chemistry 2000, July, 46, 7

    • 2,99 €
    • 2,99 €

Publisher Description

Rarely are patients hospitalized without some laboratory tests being performed, but the contribution of laboratory costs to the total costs of managing patients with different diseases has not been studied systematically. Because clinical laboratory costs, as a whole, can be readily quantified, they often become a focus of efforts to reduce expenditures in hospitals. The effectiveness of such moves has yet to be determined, although Winkelman (1) in 1984 established that laboratory costs do not decrease in proportion to the reduction of number of tests. No recent studies have been performed to verify that this is still true. Before the advent of diagnosis-related groups (DRGs) [1] in 1984, the prevailing fee-for-service approach to payments for services, including laboratory tests, encouraged excessive use of laboratory tests. There was no incentive for physicians or hospitals to be efficient in the use of tests because these generated income for the hospital. The laboratory was a revenue center for the hospital. The introduction of DRG transformed the laboratory into a cost center, with the cost of any test performed on a patient included in a DRG becoming an expense without offsetting revenue. However, instead of there being an immediate reduction in the number of tests performed, the ingrained habits of physicians continued so that ordering patterns largely went unchanged. More tests continue to be performed than probably are necessary for good management of patients. Reducing costs attributable to the laboratory would appear to be feasible both by curbing the number of tests performed and by reducing the costs of individual tests. Whereas laboratorians can influence the costs within the laboratory, few have tried to convince their clinical colleagues to change their ordering patterns. The most difficult challenge for both laboratorians and clinicians is to identify and eliminate, in advance, those tests that are not likely to have any direct influence on the diagnosis and/or management of the patient.

GENRE
Science & Nature
RELEASED
2000
1 July
LANGUAGE
EN
English
LENGTH
27
Pages
PUBLISHER
American Association for Clinical Chemistry, Inc.
SIZE
207.2
KB

More Books by Clinical Chemistry

D-Dimer Testing for Deep Venous Thrombosis: A Metaanalysis (Clinical Report) D-Dimer Testing for Deep Venous Thrombosis: A Metaanalysis (Clinical Report)
2004
Congenital Analbuminemia Attributable to Compound Heterozygosity for Novel Mutations in the Albumin Gene (Technical Briefs) Congenital Analbuminemia Attributable to Compound Heterozygosity for Novel Mutations in the Albumin Gene (Technical Briefs)
2005
Highly Sensitive Immunoprecipitation Method for Extracting and Concentrating Low-Abundance Proteins from Human Serum (Technical Briefs) Highly Sensitive Immunoprecipitation Method for Extracting and Concentrating Low-Abundance Proteins from Human Serum (Technical Briefs)
2005
Measurement of Pro-C-Type Natriuretic Peptide in Plasma (Technical Briefs) Measurement of Pro-C-Type Natriuretic Peptide in Plasma (Technical Briefs)
2005
Newborn Screening for Lysosomal Storage Disorders (Editorials) Newborn Screening for Lysosomal Storage Disorders (Editorials)
2005
Inadequate Attempts to Measure the Microheterogeneity of Transthyretin by Low-Resolution Mass Spectrometry (Letters) (Letter to the Editor) Inadequate Attempts to Measure the Microheterogeneity of Transthyretin by Low-Resolution Mass Spectrometry (Letters) (Letter to the Editor)
2005